Flint Genomics Series: Prospects of NGS Applications (Shanghai Event)
Behind the emerging industry of genetic testing, touted as a market worth hundreds of billions, a major transformation in healthcare during the internet era is poised to erupt. Will global medical development present a new landscape in 2016? What changes will the genetic testing industry undergo, and can it achieve a breakthrough? To this end,Firestone CreationSpecialLaunching the "Gene Spark" Series on Precision Medicine, Linking Investors with Entrepreneurs inThe Four Major CitiesConducting a roadshow salon to jointly explore the applications and future of NGS, at which time Firestone Creation will release the Global Gene Sequencing Map based on its existing big data database!
Guest Introduction:
Ph.D. from the Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences; Postdoctoral Fellow at the University of Zurich, Switzerland. With 15 years of experience in oncology genomic drug development, he returned to China in 2010 to found 3DMed (Siliangdi), focusing on cancer risk management, personalized therapy, and new drug development.
Previously served at the Anhui Sunny Biotechnology Research Institute and as an Employee Supervisor on the Third Supervisory Board of Anke Biotechnology. Achieved two provincial-level scientific research outcomes and received honorary titles including “Top Ten Outstanding Young Professionals of Provincial Government Agencies” (Anhui Province’s inaugural edition), “Outstanding Young Entrepreneur” of Anhui Province, and “Top Ten Outstanding Young Entrepreneurs” of Anqing City, Anhui Province. Currently serves as a Standing Committee Member of the Youth Federation of Provincial Government Agencies in Anhui Province and as Deputy General Manager of Anke Biotechnology.
Master of Science in Biology from Fudan University, MBA. Formerly served as Assistant to the General Manager at Boyang Biotechnology Co., Ltd., and Investment Director at Suzhou Longyue Venture Capital. Possesses nearly a decade of experience in entrepreneurship, corporate management, and investment within the healthcare industry. Notable investment cases include Boao Saisi (Tianjin) Biotechnology Co., Ltd. and Beijing Annoroad Gene Technology Co., Ltd.
Meeting Agenda:
• Precision Medicine’s Gene Series: Exploring the Application Prospects of NGS (Shanghai Station)
• 13:55-14:00 Opening Remarks
• 14:00-14:10 Release of the Global Map of Gene Sequencing by Huoshi Chuangzao
• 14:10-14:40 Xiong Lei, Founder and Chairman of 3D Medicines
• 14:40-15:10 Anke Biotechnology Vice General Manager Yao Jianping
• 15:10-15:40 Wang Haijiao, Executive Partner at GTJA Investment Group
• 15:40 -16:40 Roundtable Discussion
• Time:June 2 (Thursday) 13:30-16:40
• Location:B-107 Multi-functional Conference Hall, Shanghai Zhangjiang Biomedical Base Development Co., Ltd. (No. 899 Hali Road, Pudong New Area)
• Number of participants: 70
• Tea and fruit platters will be provided at the meeting.
(Note: The salon agenda is subject to minor adjustments. Please refer to the on-site arrangements for the final list of attendees and schedule.)
Recommended Attendees:
• Genomics Innovators and Entrepreneurs
• Investors in the genetics sector
• In the Field of GeneticsResearcher
Partners:GeneSpatial, VCBeat, Sequencing China, Demohealth, BioDiscoverShanghai Zhangjiang Biopharmaceutical Base
Firestone CreationFocusing on innovation and entrepreneurship services in the healthcare sector, we leverage IT capabilities to deliver unique value to healthcare entrepreneurs, facilitating their success and thereby benefiting a broader population. Huoshi’s core businesses include: Entrepreneurship MAP, a vertical engine built on machine learning, artificial intelligence, and big data analytics that synchronizes the latest global trends in healthcare innovation and entrepreneurship to accurately grasp development trajectories; Innovation LAB, which strategically invests in specific sectors based on insights from the Entrepreneurship MAP; and an early-stage lead investment fund.
VCBeatFocusing on innovation, entrepreneurship, and investment in internet healthcare, VCBeat’s four core business segments are media promotion, industry research, resource integration, and financing and investment advisory. VCBeat has become a leading voice platform in the field of internet healthcare and is widely recognized as the premier media outlet for internet healthcare venture capital and entrepreneurship. As an emerging technology media and industry research institution, it exerts profound influence on venture capital and the industrial chain within the healthcare sector.
Shanghai Zhangjiang Biopharmaceutical Base Development Co., Ltd.
Since2001In [Year], initiated the development, operation, and integrated services for “Zhangjiang Pharma Valley,”500Yu Family's biopharmaceutical startup, nearly20a multinational pharmaceutical company,80Home to a high concentration of research institutes and investment firms, “Zhangjiang Pharma Valley” is a highly dynamic hub and China’s most comprehensive biomedical innovation cluster with a well-developed innovation ecosystem.